Hanmi Group, a Korean pharmaceutical group whose listed drugmaker Hanmi Pharmaceutical (128940.KS) is a KOSPI large-cap, on July 2 promoted six executives in its first regular reshuffle since installing a professional-management structure earlier this year, according to Chosun Biz and Electronic Times (etnews). The through-line matters more than the headcount: at the operating company, the two executives elevated to vice president both sit at the center of Hanmi's obesity-drug and out-licensing strategy.
What actually changed
Three of the six promotions came at holding company Hanmi Science and three at operating company Hanmi Pharmaceutical, the group said in a statement carried by both outlets. At Hanmi Pharmaceutical, Kim Na-young, head of the Innovation Growth Division, and Choi In-young, head of the Future Growth Division, were each promoted to vice president, while Choi Jae-hyuk was newly appointed director in the obesity and metabolic unit. At Hanmi Science, Shin Jun-seop was promoted to executive vice president, Maeng Ji-woong to managing director, and Lee Jun-won to associate managing director (per etnews and Chosun Biz).
This is the first executive appointment slate signed off by CEO Hwang Sang-yeon, who Hanmi Pharmaceutical said took office early this year (Chosun Biz). Hwang is Hanmi Pharmaceutical's first externally recruited CEO in its 53-year history, drawn from the private-equity division of HB Investment, and his appointment was approved at a March 31 shareholder meeting that ended a control dispute between prior management and controlling-family interests, as reported by Seoul Economic Daily and Korea Biomedical Review.
Why these two names
Hanmi framed the moves as performance-based, and the citations point straight at its two growth engines. Kim Na-young was credited with systematizing the commercialization strategy for the H.O.P (Hanmi Obesity Pipeline) program and building its market-entry base (Chosun Biz). Her Innovation Growth Division was created in a May reorganization that consolidated the New Product Development Center, Marketing Center, Pyeongtaek manufacturing site and overseas sales team specifically to drive the rollout of obesity treatments at home and abroad, according to Seoul Economic Daily.
Choi In-young was credited with leading next-generation drug R&D and global business development, including a recent large-scale out-licensing deal and the validation of Hanmi's proprietary long-acting biologics platform, LAPSCOVERY, on the world stage (Chosun Biz). That deal is concrete: in June, Hanmi licensed Sonefpeglutide (HM15912), a long-acting GLP-2 analog for short bowel syndrome, to Eli Lilly for up to $1.26 billion (approximately ₩1.73 trillion at the exchange rate prevailing at announcement), including a $75 million non-refundable upfront payment, and the agreement explicitly validated the LAPSCOVERY platform, per Korea IT Times.
Sizing it against the company
Hanmi Pharmaceutical carried a market capitalization of roughly ₩6.34 trillion (about $4.6 billion) as of April, with shares near ₩493,500 (about $360), according to stockanalysis.com and Investing.com data. Against that base, the potential value of the single Lilly agreement — up to $1.26 billion in milestones — is equivalent to a meaningful fraction of the company's entire equity value, which helps explain why the executives tied to licensing and obesity commercialization were the ones moved up. A reshuffle that elevates the licensing and obesity leaders is, in effect, a leadership chart being redrawn around the two areas the market is already paying for.
The precedent, and the open question
The reshuffle should be read against the governance backdrop it follows. The March CEO change was not routine: it resolved a shareholder feud and broke a five-decade pattern by handing the top job to an outsider (Seoul Economic Daily, Korea Biomedical Review). A first personnel slate under such a CEO is where strategic priorities become visible, and here they cluster on obesity and out-licensing rather than legacy generics.
The test now is commercial delivery. Hanmi in April stood up a task force to commercialize its GLP-1 obesity candidate efpeglenatide, with CEO Hwang stating the aim of making it a leading Korea-origin obesity treatment, according to Seoul Economic Daily and AJU Press. The company also presented muscle-preserving obesity candidates LA-MSTN (HM500197) and Phase 1-stage LA-UCN2 (HM17321) at the American Diabetes Association 2026 sessions and maintains a pipeline of more than 20 candidates (Korea IT Times). The specific data point to watch is whether efpeglenatide reaches domestic approval and launch on the timeline Hanmi has signaled — that, not a promotion list, is what will confirm the strategy the reshuffle telegraphs.
This article is for informational purposes only and does not constitute investment advice. Figures are drawn from cited company statements and news reports as of publication; currency conversions for market capitalization and share price use an approximate rate of 1 USD = 1,370 KRW. The KRW equivalent for the Eli Lilly licensing deal reflects the exchange rate cited in the source at the time of announcement.
Sources: Chosun Biz · ET News · Seoul Economic Daily · Korea Biomedical Review · Korea IT Times
